![](/wp-content/uploads/2018/10/pmJf0wRMSuK8nmUv5PPc.png)
$599
Lilly invests in beta cell encapsulation development
Lilly and Sigilon Therapeutics announced a collaboration to develop encapsulated beta cell therapies for the potential treatment of T1DM. While other beta cell therapies have remained in early stages of development, Lilly’s financial support and considerable resources greatly increase the likelihood of Sigilon’s therapy advancing.